Analyzing Immunic (NASDAQ:IMUX) and Quoin Pharmaceuticals (NASDAQ:QNRX)

Immunic (NASDAQ:IMUX) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Immunic and Quoin Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
Quoin Pharmaceuticals	N/A	-125.60%	-64.77%

Earnings & Valuation

This table compares Immunic and Quoin Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61 million	($1.23)	-0.81
Quoin Pharmaceuticals	N/A	N/A	-$8.69 million	($2.32)	-0.10

Immunic is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Immunic and Quoin Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0	0	6	2	3.25
Quoin Pharmaceuticals	0	0	0	0	0.00

Immunic currently has a consensus target price of $13.20, suggesting a potential upside of 1,226.63%. Given Immunic’s stronger consensus rating and higher probable upside, equities analysts plainly believe Immunic is more favorable than Quoin Pharmaceuticals.

Insider & Institutional Ownership

51.8% of Immunic shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 3.0% of Immunic shares are owned by insiders. Comparatively, 3.7% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Immunic has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.

Summary

Immunic beats Quoin Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.